Pacira BioSciences (FRA:82P) FFO


FRA:82P Pacira BioSciences Inc FRA:82P
74 GF Score
Price €20.60
GF Value €25.35
! 6 Warning Signs
View Full Analysis

What is Pacira BioSciences FFO?

FFO (Funds from operations) only applies to REITs.

FRA:82P
74GF Score
Pacira BioSciences Inc FRA:82P
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pacira BioSciences (FRA:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €20.60 is trading 18.7% below its estimated GF Value™ of €25.35.

Key valuation signals for FRA:82P:

  • FFO:
  • GF Value™: €25.35 vs. price of €20.60 (18.7% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacira BioSciences Business Description

Other Exchanges PCRX:USA82P:Germany
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
74GF Score

Get the complete analysis for FRA:82P

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.60
Price
€25.35
GF Value